Fibroblasts are more effective and potent than stem cells
Fibroblast cell-based therapies will be more accessible to patients, more effective, and less expensive than stem cells.
fibrobiologics.comCrawled Nov 20, 2026
Fibroblast cell-based therapies will be more accessible to patients, more effective, and less expensive than stem cells.
FibroBiologics has filed a patent application for engineered cells designed to produce GLP-1 and other peptides continuously from inside the body.
FibroBiologics holds over 270 patents supporting its fibroblast-based regenerative medicine approach, which studies show is more effective than stem cells.
FibroBiologics pioneers fibroblast technology for regenerative medicine, with products like CYWC628 for wound healing and CYMS101 for multiple sclerosis.
The Science of Fibroblast Cell-Based Therapies Publications Publications Posters and Presentations Intriguing New Publications
FibroBiologics hosted an Investor Day Webinar on December 14, 2023, to discuss its vision, strategy, and fibroblast-based cell therapy platform.
FibroBiologics develops fibroblast cell-based therapeutics for chronic diseases.
Tom Ichim, Ph.D., serves as FibroBiologics’ scientific advisor, contributing over 20 years of biotechnology experience, including patent filings, regulatory approvals, and clinical trials.
Hamid Khoja, Ph.D., leads FibroBiologics’ research and development of cell therapy candidates as Chief Scientific Officer, with over 25 years of scientific leadership experience.
Mark Andersen, CFA, joined FibroBiologics as Chief Financial Officer in June 2022, supporting strategic financial decisions as part of the executive leadership team.
Neil Bhowmick, Ph.D. Scientific Advisory Board Cedars-Sinai Director, Cancer Biology Program, Cedars-Sinai Cancer Institute Professor of Medicine Cedars-Sinai Medical Center/UCLA. Dr. Bhowmick is on the Editorial Board of 4 scientific journals, and charter member of a NIH grant study section. He is Chief Scientific Officer for Kairos Pharma Ltd. and Armida Labs, Inc with more […]
Pete O’Heeron is Chairman, Founder, and CEO of FibroBiologics, with over 350 patents in biologics, cell therapy, and medical devices.
Stacy Coen, MBA, has served on FibroBiologics’ board of directors since July 2021, bringing over 25 years of experience in oncology and rare disease companies.
Fibrobiologics is a fibroblast biopharmaceutical company develops biologic treatments and potential cures for chronic diseases.
Fibrobiologics is treating and curing common chronic diseases with next generation fibroblast cell-based therapies.